CLINICAL NEPHROLOGY - EPIDEMIOLOGY - CLINICAL TRIALS Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study

Mignani, Renzo; Panichi, Vincenzo; Giudicissi, Antonio; Taccola, Daniele; Boscaro, Francesca; Feletti, Carlo; Moneti, Gloriano; Cagnoli, Leonardo
April 2004
Kidney International;Apr2004, Vol. 65 Issue 4, p1381
Academic Journal
Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study. Background. We sought to assess the safety and efficacy of enzyme replacement therapy (ERT) with recombinant human-α-galactosidase A (rh-α-Gal A) in kidney transplant recipients with Fabry disease, a previously unstudied population. Methods. Three male kidney transplant recipients with biochemically, genetically, and histologically confirmed Fabry disease and documented Fabry myocardiopathy received the rh-α-Gal A, agalsidase beta, 1 mg/kg of body weight every 2 weeks by intravenous infusion and were monitored biochemically, clinically, and electrocardiographically and echocardiographically for 18 months. Results. Patients showed biochemical, clinical/functional, and morphologic response to ERT. Plasma globotriaosylceramide decreased 23% to 50%. Extremity pain resolved within 2 months in the patient with this manifestation. On echocardiography, left ventricular mass, end diastolic diameter (EDD), and cardiac contractility, shown by ejection fraction (EF), improved in 2 of the 3 patients receiving essentially all planned infusions. EDD and EF remained basically stable, but cardiac morphologic abnormalities progressed in the other patient, who had a 5-month interruption in ERT after the initial month. Mild mitral insufficiency persisted in all patients, as did atrial fibrillation in the affected individual. After a combined total of 116 infusions, no treatment-related adverse event, intolerance, or seroconversion was seen. Renal function remained stable and the immunosuppression regimen unchanged in all patients. Conclusion. Our pilot study provides preliminary evidence that ERT with agalsidase beta, 1 mg/kg every 2 weeks, is safe and often effective against extra-renal manifestations in kidney transplant patients with Fabry disease. Studies with longer courses of this and higher doses of ERT are merited in this population.


Related Articles

  • Trichosporon beigelii Funguria in Renal Transplant Recipients. Lussier, N.; Laverdiere, M.; Delorme, J.; Weiss, K.; Dandavino, R. // Clinical Infectious Diseases;11/1/2000, Vol. 31 Issue 5, p1299 

    Presents a study on the trichosporon beigelii funguria in renal transplant patients. Information on trichosporon beigelii; Details on renal transplant recipients who experienced trichosporon beigelii funguria; Use of antifungal therapy for invasive infections caused by trichosporon beigelii.

  • Immunosuppressants.  // Reactions Weekly;9/3/2011, Issue 1367, p23 

    The article describes the clinical cases of four renal transplant patients who developed malignancies associated with their disused arteriovenous fistulae (AVF) while under immunosuppressant therapies.

  • Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation. Aasebø, Willy; Strøm, Erik H.; Hovig, Torstein; Undset, Liv H.; Heiberg, Arvid; Jenssen, Trond // NDT Plus;Jun2010, Vol. 3 Issue 3, p303 

    Enzyme replacement therapy (ERT) has been introduced for Fabry disease and has been reported to clear some renal cell types of accumulated glycolipids and to reduce the accumulation in other cell types. We describe two patients without Fabry disease who were transplanted with kidney allografts...

  • Does antihypertensive therapy modify chronic allograft failure? Raine, Anthony E. G. // Kidney International Supplement;Dec1995, Issue 52, pS-107 

    Hypertension after renal transplantation continues to affect 50% or more of patients, despite use of modern immunosuppressive regimens. Relationships between poor control of blood pressure and reduced chronic allograft, survival have been clearly demonstrated, and arc analogous to the well-known...

  • The Granzyme B Inhibitor SERPINB9 (Protease Inhibitor 9) Circulates in Blood and Increases on Primary Cytomegalovirus Infection after Renal Transplantation. Rowshani, Ajda T.; Strik, Merel C. M.; Molenaar, Rosalie; Si-La Yong; Wolbink, Angela M.; Bemelman, Frederike J.; Hack, C. Erik; Berge, Ineke J. M. Ten // Journal of Infectious Diseases;12/1/2005, Vol. 192 Issue 11, p1908 

    SERPINB9 is the only known human intracellular inhibitor of granzyme B (GrB), the effector molecule in immunity against cytomegalovirus (CMV) and in renal allograft rejection. Therefore, using specific enzyme-linked immunosorbent assays, we addressed the presence of circulating SERPINB9 during...

  • Drug-Induced Cytopenias Appear to Be Self-Limited. Hong, J.C.; Kahan, B.D. // Kidney;Nov/Dec2000, Vol. 9 Issue 6, p268 

    Deals with a study that assessed the factors that predispose renal transplant recipients to thrombocytopenia and leukopenia after the administration of sirolimus combined with a cyclosporine and prednisone regimen. Methodology; Results; Conclusion.

  • Outcome of Kidney Transplantation in Patients with Fabry Disease. Cybulla, Markus // Current Medical Literature: Lysosomal Storage Disease;2011, Vol. 9 Issue 2, p43 

    The article examines the results of kidney transplantation in patients with Fabry disease. It offers information on Fabry disease which is reportedly a storage disorder resulting from a deficiency of lysosomal enzyme a-galactosidase A. Renal transplantation is reportedly a promising treatment...

  • Sirolimus.  // Reactions Weekly;6/12/2004, Issue 1005, p13 

    Discusses research being done on the side effects of the drug sirolimus on a renal transplant recipient. Reference to a study by S. F. Chen et al published in the August 2003 issue of "Journal of the Formosan Medical Association"; Therapeutic reason behind the use of the drug; Development of...

  • Efficacy and safety of alendronate in the prevention of bone loss in renal transplant recipients. Shahbazian, H.; Mowla, K.; Shahbazian, H. B.; Peydayesh, B.; Ehsanpour, A. // Indian Journal of Nephrology;Apr-Jun2007, Vol. 17 Issue 2, p61 

    Background: The rapid loss of bone mass density occurs immediately after transplantation; this contributes to an increased risk for osteoporosis and fractures. The prevention and management of bone loss after renal transplantation is not elucidated thus far. The purpose of this study was to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics